Gross margin outlook
Search documents
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook (NASDAQ:KRYS)
Seeking Alpha· 2026-02-17 20:55
Group 1 - The article does not provide any relevant content regarding the company or industry [1]
